Ercole Brusamolino

Policlinico San Matteo Fondazione — Italy

Medicine · Health Sciences

40h-index8.4kcitations149works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(91), Chronic Lymphocytic Leukemia Research(51), Acute Myeloid Leukemia Research(34), Acute Lymphoblastic Leukemia research(26), Lung Cancer Treatments and Mutations(24)

Publications149 total

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
The Lancet Oncology·2017· 129 citedOpen Access
Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Journal of Clinical Oncology·2016· 146 citedOpen Access
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)
Leukemia & lymphoma/Leukemia and lymphoma·2016· 7 cited
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant
Bone Marrow Transplantation·2015· 12 cited
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
Bone Marrow Transplantation·2014· 51 cited
THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
SHILAP Revista de lepidopterología·2014Open Access
[ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
Journal of Clinical Oncology·2014· 161 citedOpen Access
Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
Journal of Clinical Oncology·2014· 381 citedOpen Access
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
British Journal of Haematology·2014· 35 citedOpen Access
The PI3K-δ Inhibitor TGR-1202 In Combination With Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization In Hodgkin Lymphoma Cell Lines
Blood·2013· 1 cited
Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose Dense Chemotherapy: A Study of The Fondazione Italiana Linfomi (FIL)
Blood·2013
The PI3K/ERK Dual Inhibitor AEZS-136 Induces ROS-Dependent Necroptotic Cell Death and Exerts Potent Antitumor Effects In NOD/SCID Mice With Hodgkin Lymphoma Cell Line Xenografts
Blood·2013· 2 cited
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
Haematologica·2013· 72 citedOpen Access
Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL)
Blood·2012· 30 cited
Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group
Blood·2012· 5 cited
Mobilization of Hematopoietic Stem Cells by a Bendamustine-Containing Regimen in Hodgkin's Lymphoma
Blood·2012· 2 cited
Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma
Blood·2012· 39 cited
Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)
Blood·2012· 5 cited
THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY
Mediterranean Journal of Hematology and Infectious Diseases·2012· 14 citedOpen Access
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
Haematologica·2011· 69 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Mario Lazzarino(28), Carlo Bernasconi(16), Francesco Passamonti(14), G. Pagnucco(13), Luca Arcaini(12), Enrica Morra(12), Ester Orlandi(12), Cristiana Pascutto(10), Ester Orlandi(9), Pier Luigi Zinzani(8), Umberto Vitolo(7), Francesco Zaja(7), Paolo Bernasconi(7), Alessandro Pulsoni(6), C. Astori(6), Marco Paulli(6), Flavia Salvi(5), Armando Santoro(5), Maurizio Bonfichi(5), Pinuccia Valagussa(4)